Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Hospital Mortality in Patients Submitted to Pharmacoinvasive Strategy With Tenecteplase (TNK)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Felipe José de Andrade Falcão, Federal University of São Paulo
ClinicalTrials.gov Identifier:
NCT01791764
First received: February 8, 2013
Last updated: February 12, 2013
Last verified: February 2013

February 8, 2013
February 12, 2013
November 2010
October 2012   (final data collection date for primary outcome measure)
Hospital Mortality [ Time Frame: During hospital stay,an expected average of 15 days ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01791764 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Hospital Mortality in Patients Submitted to Pharmacoinvasive Strategy With Tenecteplase (TNK)
Hospital Mortality After ST Segment Elevation Acute Myocardial Infarction Submitted to Pharmacoinvasive Strategy With Tenecteplase (TNK): Analysis of 398 Patients.

This study has the following objective:

To identify related factors to hospital mortality in patients with ST-segment elevation acute myocardial infarction submitted to pharmacoinvasive strategy within a structured healthcare network.

Primary percutaneous coronary intervention is the main therapy for patients with ST-segment elevation acute myocardial infarction. However, a significant portion of these patients won't receive optimal treatment due to the small number of tertiary centers with interventional laboratories available for 24 hours a day, 7 days a week.

Specially in large urban centers and rural areas, where tertiary care hospitals are restricted to a specific region, alternative approaches must be developed. The pharmacoinvasive strategy has emerged as an alternative for patients admitted to primary care centers. It is based in up-front intravenous thrombolytic therapy and transfer to a tertiary center where early, systematic, coronary intervention will be performed between 3 to 24 hours after the administration of thrombolytic drugs, even in cases in which successful reperfusion was obtained.

Observational [Patient Registry]
Observational Model: Cohort
Time Perspective: Prospective
15 Days
Not Provided
Non-Probability Sample

The patients will be selected from primary care clinic.

Acute Coronary Syndrome
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
368
October 2012
October 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Clinical diagnosis of ST-segment elevation acute myocardial infarction submitted to pharmacoinvasive strategy with tenecteplase.

Exclusion Criteria:

  • Absence of obstructive coronary disease
  • Surgical reference
  • Did not undergo catheterization
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Brazil
 
NCT01791764
SAMU-01
Yes
Felipe José de Andrade Falcão, Federal University of São Paulo
Federal University of São Paulo
Not Provided
Principal Investigator: Felipe JA Falcao Federal University of Sao Paulo
Principal Investigator: Claudia MR Alves, Doctor Federal University of Sao Paulo
Study Director: Antonio CC Carvalho Federal University of Sao Paulo
Study Director: Adriano HP Barbosa Federal University of Sao Paulo
Federal University of São Paulo
February 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP